{
  "ptid_time": "016_S_4591_2012-06-14",
  "img_path": "/data/qiuhui/data/adni/images/016_S_4591/2012-06-14/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 15,155 mm³, 32.2% below the reference mean. With a Z-score of -0.80 (21.1th percentile), this represents normal volume ; whole brain volume measures 936,941 mm³, 9.0% below the reference mean. With a Z-score of -1.12 (13.2th percentile), this represents mild atrophy; entorhinal cortex volume measures 2,626 mm³, 32.5% below the reference mean. With a Z-score of -2.52 (0.6th percentile), this represents significant atrophy; fusiform gyrus volume measures 14,919 mm³, 18.1% below the reference mean. With a Z-score of -2.04 (2.1th percentile), this represents significant atrophy; middle temporal gyrus volume measures 18,014 mm³, 12.2% below the reference mean. With a Z-score of -1.09 (13.9th percentile), this represents mild atrophy. ",
  "text_data": "Age is 65.9 years. Gender is Female. Education: 13 years. Handedness: Right. Race: White. Medical history: Psychiatric; Head, Eyes, Ears, Nose and Throat; Musculoskeletal; Endocrine-Metabolic; Allergies or Drug Sensitivities; Major Surgical Procedures. MMSE: 23.0. MoCA: 21.0. Logical Memory: 0.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.65 SUVR (profound elevated); Amyloid beta: 651.00 pg/mL (normal ); Total tau: 305.30 pg/mL (normal ); Phosphorylated tau: 28.67 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in the entorhinal cortex and fusiform gyrus, which are key regions affected in Alzheimer's disease (AD), along with mild whole brain and middle temporal gyrus atrophy. Despite normal CSF biomarkers (Aβ, T-tau, P-tau), the profoundly elevated AV45 (amyloid PET) suggests amyloid pathology. Cognitive scores (MMSE 23, MoCA 21) indicate mild impairment. The APOE4 carrier status further increases AD risk.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely due to Alzheimer's pathology, given amyloid PET positivity and medial temporal atrophy).  \n\n**Confidence:** **Medium** (CSF biomarkers are normal, which is atypical for AD, but amyloid PET and structural changes strongly support neurodegenerative pathology).",
  "timestamp": "2025-07-26T00:27:29.260503"
}